Novel Schizophrenia Risk Gene TCF4 Influences Verbal Learning and Memory Functioning in Schizophrenia Patients

Leonhard Lennertz a  Dan Rujescu b  Michael Wagner a  Ingo Frommann a
Svenja Schulze-Rauschenbach a  Anna Schuhmacher a  Martin W. Landsberg a
Petra Franke c  Hans-Jürgen Möller b  Wolfgang Wölwer c  Wolfgang Gaebel c
Heinz Häfner d  Wolfgang Maier a  Rainald Mössner a

a Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, b Department of Psychiatry and Psychotherapy, University of Munich, Munich, c Department of Psychiatry and Psychotherapy, University of Düsseldorf, Düsseldorf, and d Central Institute of Mental Health, Mannheim, Germany

Introduction

Schizophrenia is a severe and disabling disorder which belongs to the most burdensome and costly illnesses worldwide [1]. The disorder is characterized by several disturbances in affect, cognition and behavior. Family studies and twin studies investigating the heritability of schizophrenia substantiate a high genetic liability of schizophrenia which is estimated to explain up to 85% of the variance [2].

Due to the waning and waxing course of the disorder, it has been emphasized to regard the underlying neurobiological core features instead of the observable phenotype. These intermediate phenotypes, or endophenotypes, are assumed to mediate genetic and phenotypic variation [3, 4]. Neurocognitive features have proven...
highly promising endophenotypes in schizophrenia research [5]. Among others, deficits in verbal declarative memory (VDM) have been investigated extensively, yielding standardized effect sizes up to 1.41 (Cohen’s d) [6]. Thus, patients suffering from schizophrenia show marked deficits in verbal learning, retrieval and recognition [7]. Faroone et al. [8] demonstrated the cosegregation of verbal memory and schizophrenia liability. In their analyses, subjects with two or more affected family members (multiplex families) showed worse memory functioning than subjects with only one affected family member (simplex families) and healthy control subjects. In unaffected relatives, VDM deficits up to d = 0.65 were obtained, compared to healthy control subjects [9–11].

Recently, a large genome-wide association study (GWAS) was performed, reporting a novel genetic variant conferring a risk for schizophrenia [12]. This variant is located within intron 3 of transcription factor 4 (TCF4). The C allele of the rs9960767 polymorphism was found to be more frequent in patients with schizophrenia, leading to a 1.23-fold higher risk for the disorder. The TCF4 gene is located on chromosome 18q21.2. In their genome scan metaanalysis of linkage studies on schizophrenia, Lewis et al. [13] found the 18q21.1-qter ‘bin’ ranked around fifteenth in the genome. The TCF4 gene is involved in normal brain development [14] and has been associated with the Pitt-Hopkins syndrome, a severe encephalopathy with autonomic dysfunctions like intermittent hyperventilation [15–18]. Recently, Kalscheuer et al. [19] reported a de novo translocation disrupting exon 4 of TCF4 in a girl with mental retardation, thus suggesting that there are also milder phenotypic expressions of TCF4 variability compared to the Pitt-Hopkins syndrome.

Since VDM impairments have been related to abnormal hippocampal and prefrontal volume and activation in both schizophrenia patients and unaffected relatives [20, 21], we hypothesized that the TCF4 gene may influence neurodevelopment and thus alters VDM functioning. Following previous results of a recent GWAS, we tested for an association of the risk-conferring C allele of the rs9960767 polymorphism with impaired VDM functioning in schizophrenia patients.

Patients and Method

Sample
For the present investigation, we assessed 401 patients suffering from schizophrenia. All participants had given their written informed consent prior to inclusion. The patients were recruited in the Departments of Psychiatry of the Universities of Bonn, Cologne, Düsseldorf, Mannheim, Berlin, Tübingen, Jena and Munich. Diagnoses were established according to criteria of the DSM-IV or ICD-10 [22, 23]. Subjects were excluded when diagnosed with any neurological disorder. Blood samples were collected and stored in the molecular genetics laboratories at the departments of psychiatry and psychotherapy of the universities of Bonn and Munich for genotyping.

Measures
VDM was assessed by the Rey Auditory Verbal Learning Test (RAVLT; German translation: Verbaler Lern- und Merkfähigkeits-test) [24]. The RAVLT is a highly reliable and valid test for VDM. Subjects are asked to learn a list (list A) of 15 words over 5 trials. After that, a second list (list B), consisting of 15 new words which have to be learned, is presented. Immediately after this interference list and again after 30 min, free recall of list A is assessed (delayed recall). Recognition is measured by words read aloud. The test person is asked to categorize these words as belonging to list A, list B or a new list never presented. The RAVLT provides a number of different measures of VDM, all of which generally indicate impairments in schizophrenia patients. In order to restrict analyses and to reduce the probability of false-positive results due to a error accumulation, we selected 4 dependent variables: (1) recalled items from the first learning trial (short-term memory); (2) the sum of recalled items over the 5 learning trials (total learning); (3) delayed recall after 30 min (delayed recall); and (4) the sum of correctly recognized items of list A (recognition).

In 198 schizophrenia patients, verbal intelligence was estimated based on the score in a German vocabulary test, the Mehrfachwahl-Wortschatz-Test (MWT-B) [25]. In the remaining 203 schizophrenia cases, the German translation of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) was used to measure intelligence [26].

Genotyping
DNA for single-nucleotide polymorphism (SNP) genotyping was isolated from EDTA anticoagulated blood using the Qiagen protocol for the Blood & Cell Culture DNA Maxi Kit (Qiagen, Hilden, Germany). PCR was performed using 12.5 ng of DNA, the Taqman® Universal PCR MasterMix, No AmpErase® UNG and Taqman SNP Genotyping Assays for the SNP (all provided by Applied Biosystems, Foster City, Calif., USA) according to the protocol for Taqman SNP genotyping (Applied Biosystems). Each assay consisted of the unlabeled forward and reverse primers and the FAM- and VIC-dye-labeled MGB probes. Those assays are designed for allelic discrimination of specific SNP. Both alleles were scored in a single well by measuring the fluorescence at the end of the PCR, using a Tecan Ultra 384 reader (Tecan, Crailsheim, Germany). The excitation and emission wavelengths for the FAM-labeled probes were 485 and 535 nm, and for the VIC-labeled probes, 535 and 590 nm, respectively.

Statistics
All analyses were carried out at a significance level of p = 0.05. In order to eliminate center effects, RAVLT data were standardized using z-transformation (mean = 0; SD = 1). Similarly, MWT-B and WAIS-R data were standardized and Z scores aggregated into 1 variable. VDM performance differences were assessed us-
ing ANOVA with standardized VDM variables as dependent vari-
ables, and genotype or medication status as the independent var-
iable. Pearson correlations were computed to analyze the relation
between duration of illness and VDM. All analyses were com-
puted using the SPSS package, version 17.0.

Results

The descriptive characteristics, genotype distribution
and allele frequencies of the sample are displayed in ta-
ble 1. The TCF4 variant was in Hardy-Weinberg equilib-
rium in the present study (p = 0.068). As expected, the
frequency of the C allele was only 6%. Since the CC geno-
type of the rs9960767 polymorphism was present in only
4 patients, subjects with either a CA or a CC genotype
were combined and compared against subjects carrying
the AA genotype in all subsequent analyses.

With regard to the demographic characteristics of the
sample, no differences were found between TCF4 geno-
types in any of the variables age (F = 0.349; d.f. = 1; p =
0.555), gender (χ² = 0.027; d.f. = 1; p = 0.870) and intel-
ligence (F = 0.023; d.f. = 1; p = 0.881). The same was true
for the clinical characteristics of the patient sample: age
at onset, duration of illness, medication type and DSM-
IV subtype were not related to TCF4 genotype (table 2).
To analyze the effect of differential drug treatment, we
compared schizophrenia patients treated with at least 1
atypical antipsychotic (n = 241) with those being treated
with only conventional neuroleptics (n = 58). However,
none of the memory parameters analyzed were affected
by the type of drug treatment in our study (all p > 0.20).
Correlation analyses indicated a small correlation of du-
ration of illness with recognition (r = 0.123; p = 0.016;
adjusted for age).

Next, we analyzed VDM performance as a function of
the TCF4 genotypes. No significant associations between
TCF4 genotype and immediate recall (F = 1.25; d.f. = 1;
p = 0.264) and total learning (F = 2.36; d.f. = 1; p = 0.125)
were found. A trend toward higher performance in CA/
CC genotype carriers in delayed recall emerged (AA ge-
one: 9.41 ± 3.62; CA/CC genotype: 10.24 ± 3.27; F =
2.93; d.f. = 1; p = 0.088) (fig. 1). Moreover, in recognition,
this genotype was significantly associated with better per-
formance compared to carriers of the AA genotype (AA
genotype: 13.06 ± 2.20; CA/CC genotype: 13.76 ± 1.22;
F = 3.90; d.f. = 1; p = 0.049) (fig. 1). When using age, gen-
der, intelligence and duration of illness as covariates, this
was a trend finding (AA genotype: 13.09 ± 1.08; CA/CC
genotype: 13.66 ± 2.90; F = 2.76; d.f. = 1; p = 0.098), while
no effect was found for the remaining memory variables was found.

Discussion

This study investigated the novel schizophrenia can-
didate gene TCF4, which previously was reported to be
associated with the disorder in a large GWAS [12]. Based
on the study conducted by Stefánsson et al. [12] and on
the extensive literature documenting highly replicable
memory deficits in schizophrenia, we had hypothesized
that schizophrenia subjects carrying the disease-associ-
ated C allele of the variant rs9960767 would show im-
paired verbal memory functioning. Contrary to our a pri-
or assumption, patients with this allele performed sig-
ificantly better with regard to recognition. Moreover, a
trend toward a higher mean in recalled words after the
30-min delay was found in C allele carriers. There was no
other statistical relationship between VDM deficits and
TCF4 genotype.

Table 1. Genotype information and demographic characteristics
of schizophrenia patients (n = 401)

| Age, years  | 37.8 ± 10.9 |
| Gender, % male | 58.1 |
| IQ          | 105.2 ± 17.7 |
| CC/CA/AA, n | 4/45/352 |
| Allele A frequency | 0.934 |
| Allele C frequency | 0.066 |

Age and IQ are shown as means ± SD. IQ = Intelligence mea-
sured by MWT-B or WAIS-R.
The TCF4 gene has been reported to be involved in brain development [14]. Prior studies have shown a role of TCF4 in the Pitt-Hopkins syndrome [15], a severe neurodevelopmental disorder with serious physiological abnormalities [16–18]. Since a de novo translocation disrupting exon 4 of TCF4 was recently seen in a girl with mental retardation, TCF4 is also implicated in milder forms of cognitive disabilities compared to the Pitt-Hopkins syndrome [19]. We therefore investigated the potential role of this gene in neuropsychological dysfunctions in schizophrenia. The studies on the Pitt-Hopkins syndrome and that conducted by Kalscheuer et al. [19], both relating the TCF4 gene to mental disabilities, also indicate an influence of TCF4 on general intellectual functioning. However, in our study the TCF4 genotype did not affect intelligence in subjects with schizophrenia. Although we had to discard our main hypothesis regarding a link between impaired memory functioning and the C allele of the rs9960767, the results of the present investigation suggest a role of TCF4 in the development of memory-related neuronal structures.

There are several areas of the central nervous system involved in memory functioning. Since studies on patients with lesions of the prefrontal cortex (PFC) and the medial-temporal lobe (MTL) found impaired memory in these patients, numerous studies have investigated the role of the PFC and MTL in memory function [27, 28]. Studies linking memory performance with neuronal volume and activation in schizophrenia are in line with the findings in healthy subjects. With regard to MTL, a well-documented reduction in hippocampus volume in schizophrenia patients is evident [29–31]. These abnormal findings from volumetric studies are further encouraged by fMRI studies investigating regional activation during memory tasks. Heckers et al. [32, 33] reported a series of studies linking reduced activity in the hippocampus and impaired verbal memory function in schizophrenia patients. A recent metaanalysis including 18 imaging studies replicated the finding of reduced activation of the hippocampus during encoding and retrieval in schizophrenia [20]. The PFC has been related to memory deficits in schizophrenia following the observation that most schizophrenia patients do not utilize semantic coding strategies during encoding. In line with this, it has been reported that VDM deficits in schizophrenia patients attenuate after a systematic training in semantic coding strategies, or due to a different presentation of the material [34, 35]. In their metaanalysis, Achim and LePage [20], among others, found a consistently reduced activation of the left inferior PFC in different learning and memory tasks in schizophrenia patients compared to healthy control subjects. Other studies including those by Heckers et al. [32, 33] mentioned above found elevated activity patterns in the PFC during encoding and retrieval [36]. Of particular interest for the present study are investigations reporting hippocampal data from unaffected high-risk subjects and relatives of schizophrenics. In high-risk subjects, a reduced hippocampal volume has been demonstrated [37]. Seidman et al. [38] also found abnormally reduced hippocampi in unaffected first-degree relatives of schizophrenia patients. Moreover, left hippocampal volumes in relatives were positively related to VDM deficits found in comparison to healthy control subjects [21]. These results stress a genetically determined abnormal hippocampus volume in schizophrenia patients and their relatives, and thus emphasize a developmental view of the disorder with VDM deficits inherited within families. Summing up the evidence on neuronal activation and memory in schizophrenia, a well-replicated insufficiency in the recruitment of the MTL and ab-

Table 2. Clinical characteristics of schizophrenia patients stratified for genotype

<table>
<thead>
<tr>
<th></th>
<th>AA</th>
<th>CA/CC</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset, years (n = 385)</td>
<td>25.8 ± 8.9</td>
<td>24.4 ± 7.9</td>
<td>t = 0.985; p = 0.325</td>
</tr>
<tr>
<td>Duration of illness, years (n = 385)</td>
<td>12.1 ± 9.6</td>
<td>12.1 ± 9.9</td>
<td>t = 0.003; p = 0.997</td>
</tr>
<tr>
<td>Schizophrenia subtypea, % (n = 394)</td>
<td>74.0:26.0</td>
<td>68.8:31.3</td>
<td>χ² = 0.592; p = 0.442</td>
</tr>
<tr>
<td>Type of medicationb, % (n = 299)</td>
<td>19.8:80.2</td>
<td>16.2:83.8</td>
<td>χ² = 0.273; p = 0.601</td>
</tr>
</tbody>
</table>

Age and duration of illness are shown as means ± SD. Different numbers are due to missing data.

a Ratio of paranoid subtype versus other subtypes.

b Ratio of patients treated with only typical antipsychotics versus patients treated with any atypical antipsychotic.
normal activation of the PFC have been reported during memory task performance in schizophrenia patients and their unaffected relatives. These results prompted us to assume a potential link between TCF4 and memory-related structures which we indirectly tested using VDM data from schizophrenia patients. However, we were not able to analyze structural hippocampal data in our study. Further research should address the relation of TCF4 variation to hippocampal volume or activation.

VDM constitutes an excellent endophenotype of schizophrenia which has already provided noticeable results in the search for candidate genes in the last years. For instance, the met allele of the brain-derived neurotrophic factor 1 gene has been repeatedly associated with memory deficits in patients suffering from schizophrenia [39–41] and their unaffected first-degree relatives [42]. Moreover, VDM deficits precede acute psychotic episodes [43] and tend to be stable even after antipsychotic treatment with second generation neuroleptics [5]. In our study, this was supported by the finding that atypical drug treatment was not superior to conventional antipsychotic treatment when cognitive functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading. Biol Psychiatry 2000;48:120–126.


References


